Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 13Cholangiocarcinoma 2Pancreatic Neoplasms 1Locally Advanced Thyroid Gland Carcinoma 1Liver Neoplasms 1Hepatocellular Carcinoma with PVTT 1Digestive System Neoplasms 1Differentiated Thyroid Cancer 1Diabetes Mellitus 1Cirrhosis, Familial, with Pulmonary Hypertension 1Carcinoma 1Biliary Tract Adenocarcinoma 1Biliary Malignant Tumors 1

Interventions

Cisplatin 24Carboplatin 19Paclitaxel 18pembrolizumab 12Gemcitabine 12Radiotherapy 9Fluorouracil 9Specimen Handling 8Magnetic Resonance Spectroscopy 7cemiplimab 6Platinum 6Nivolumab 6Docetaxel 6Cetuximab 61,2-diaminocyclohexaneplatinum II citrate 6epothilone B 5anlotinib 5Sunitinib 5Pemetrexed 5Oxaliplatin 5Everolimus 5Drug Therapy 5Cyclophosphamide 5Capecitabine 5Bevacizumab 5durvalumab 4Radiotherapy, Intensity-Modulated 4Radiation 4Erlotinib Hydrochloride 4Celecoxib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma × donafenib × Clear all
NCT04962958 2023-06-22

Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Unknown
30 enrolled
Gastrointestinal

Carcinoma, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡